Delaware Governor Meyer (far right) and Delaware Division of Small Business Director Bell (center) join the CorriXR leadership team to announce the state's $1M investment in the company.
CorriXR Therapeutics Secures $1M Investment from State of Delaware
NEWARK, Del.–(BUSINESS WIRE)–CorriXR Therapeutics, Inc., a pioneering oncology-focused biotherapeutics company, has announced a significant milestone with a $1M investment from the State of Delaware. This funding will be instrumental in advancing CorriXR’s lead program aimed at developing next-generation treatments for solid tumors, with particular focus on head and neck, and lung cancers.
This investment not only underscores the potential of CorriXR’s cutting-edge therapies but also highlights Delaware’s commitment to supporting innovative early-stage companies.
“We’re excited to have the State of Delaware participate in our Series A financing round as we advance toward our first-in-human clinical trial,” said Eric Kmiec, Ph.D., founder & CEO of CorriXR. “This investment will be critical as we complete preclinical studies, scale-up manufacturing, and prepare our investigational new drug (IND) submission.”
